PLSE (Pulse Biosciences, Inc.) — Stock Analysis, Catalysts & AI Research

Pulse Biosciences, Inc.

$26.32

Health CareMedical - Instruments & Supplies

The Read: Pulse Biosciences’ stock fell about 23% after Q4 2025 earnings met estimates but 2026 commercial guidance disappointed due to slower Cell-Surgical System adoption, then rose slightly after initiating NANOPULSE-AF trial and presenting positive data.

Price

Overlays

Panel

PLSE

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Pulse Biosciences, Inc.

$26.32

Health CareMedical - Instruments & Supplies

Price

Overlays

Panel

PLSE

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Create your free account to unlock active Expected Moves for PLSE

Expected Moves

Pulse Biosciences, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow

Create your free account to unlock active Expected Moves for PLSE

Expected Moves

Pulse Biosciences, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow